Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas
- PMID: 25759534
- PMCID: PMC4351216
- DOI: 10.3748/wjg.v21.i9.2658
Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas
Abstract
Aim: To compare characteristics and outcomes of resected and nonresected main-duct and mixed intraductal papillary mucinous neoplasms of the pancreas (IPMN).
Methods: Over a 14-year period, 50 patients who did not undergo surgery for resectable main-duct or mixed IPMN, for reasons of precluding comorbidities, age and/or refusal, were compared with 74 patients who underwent resection to assess differences in rates of survival, recurrence/occurrence of malignancy, and prognostic factors. All study participants had dilatation of the main pancreatic duct by ≥ 5 mm, with or without dilatation of the branch ducts. Some of the nonsurgical patients showed evidence of mucus upon perendoscopic retrograde cholangiopancreatography or endoscopic ultrasound and/or after fine needle aspiration. For the surgical patients, pathologic analysis of resected specimens confirmed a diagnosis of IPMN with involvement of the main pancreatic duct or of both branch ducts as well as the main pancreatic duct. Clinical and biologic follow-ups were conducted for all patients at least annually, through hospitalization or consultation every six months during the first year of follow-up, together with abdominal imaging analysis (magnetic resonance cholangiopancreatography or computed tomography) and, if necessary, endoscopic ultrasound with or without fine needle aspiration.
Results: The overall five-year survival rate of patients who underwent resection was significantly greater than that for the nonsurgical patients (74% vs 58%; P = 0.019). The parameters of age (< 70 years) and absence of a nodule were associated with better survival (P < 0.05); however, the parameters of main pancreatic duct diameter > 10 mm, branch duct diameter > 30 mm, or presence of extra pancreatic cancers did not significantly influence the prognosis. In the nonsurgical patients, pancreatic malignancy occurred in 36% of cases within a mean time of 33 mo (median: 29 mo; range: 8-141 mo). Comparison of the nonsurgical patients who experienced disease progression with those who did not progress showed no significant differences in age, sex, symptoms, subtype of IPMN, or follow-up period; only the size of the main pancreatic duct was significantly different between these two sub-groups, with the nonsurgical patients who experienced progression showing a greater diameter at the time of diagnosis (> 10 mm).
Conclusion: Patients unfit for surgery have a 36% greater risk of developing pancreatic malignancy of the main-duct or mixed IPMN within a median of 2.5 years.
Keywords: Main-duct intraductal papillary mucinous neoplasms; Natural history; Pancreatic surgery; Prognosis; Risk of malignancy.
Figures



Similar articles
-
Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.Surgery. 2015 Oct;158(4):937-44; discussion 944-5. doi: 10.1016/j.surg.2015.06.003. Epub 2015 Jul 11. Surgery. 2015. PMID: 26173683
-
Evolution of incidental branch-duct intraductal papillary mucinous neoplasms of the pancreas: A study with magnetic resonance imaging cholangiopancreatography.World J Gastroenterol. 2016 Nov 21;22(43):9562-9570. doi: 10.3748/wjg.v22.i43.9562. World J Gastroenterol. 2016. PMID: 27920477 Free PMC article.
-
Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms.Endoscopy. 2010 Dec;42(12):1077-84. doi: 10.1055/s-0030-1255971. Epub 2010 Nov 30. Endoscopy. 2010. PMID: 21120776
-
Current roles of endoscopy in the management of intraductal papillary mucinous neoplasm of the pancreas.Dig Endosc. 2015 May;27(4):450-457. doi: 10.1111/den.12434. Epub 2015 Feb 5. Dig Endosc. 2015. PMID: 25588761 Free PMC article. Review.
-
[Branch duct intraductal papillary mucinous neoplasm - contra resection].Chirurg. 2017 Nov;88(11):918-926. doi: 10.1007/s00104-017-0495-z. Chirurg. 2017. PMID: 28871376 Review. German.
Cited by
-
Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process.BMC Surg. 2019 Aug 22;19(1):115. doi: 10.1186/s12893-019-0580-y. BMC Surg. 2019. PMID: 31438917 Free PMC article.
-
Carcinoembryonic antigen level in the pancreatic juice is effective in malignancy diagnosis and prediction of future malignant transformation of intraductal papillary mucinous neoplasm of the pancreas.J Gastroenterol. 2019 Nov;54(11):1029-1037. doi: 10.1007/s00535-019-01592-8. Epub 2019 May 20. J Gastroenterol. 2019. PMID: 31111221
-
Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.Langenbecks Arch Surg. 2018 Mar;403(2):151-194. doi: 10.1007/s00423-017-1644-z. Epub 2017 Dec 7. Langenbecks Arch Surg. 2018. PMID: 29218397
-
Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective.Surgery. 2020 Oct;168(4):601-609. doi: 10.1016/j.surg.2020.04.052. Epub 2020 Jul 29. Surgery. 2020. PMID: 32739138 Free PMC article.
-
Natural History of Pancreatic Cysts.Dig Dis Sci. 2017 Jul;62(7):1770-1777. doi: 10.1007/s10620-017-4542-x. Epub 2017 Mar 17. Dig Dis Sci. 2017. PMID: 28315034 Review.
References
-
- Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977–987. - PubMed
-
- Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32. - PubMed
-
- Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K; International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197. - PubMed
-
- Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg. 2007;246:644–651; discussion 651-654. - PubMed
-
- Nagai K, Doi R, Kida A, Kami K, Kawaguchi Y, Ito T, Sakurai T, Uemoto S. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg. 2008;32:271–278; discussion 279-280. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical